Table 2.
Patient characteristics.
| Variables | Patients (n=75) |
|---|---|
| Age (y)a | 2.3 (0.4–11.2) |
| Male gender (%) | 39 (52.0) |
| Height (cm)a | 87 (60–145) |
| Weight (kg)a | 12.0 (5.5–35.0) |
| CTP scorea | 8 (5–14) |
| PELD scorea | 6 (−11–45) |
| Indication for LT (%) | |
| Biliary atresia | 38 (50.7) |
| Irreversible graft failureb | 11 (14.7) |
| UCDsc | 7 (9.3) |
| Hepatoblastoma | 3 (4.0) |
| MMA | 3 (4.0) |
| PFIC | 3 (4.0) |
| Othersd | 10 (13.3) |
Data are mean (range).
Irreversible graft failure may result from primary nonfunction or vascular or biliary complications after liver transplantation.
Ornithine transcarbamylase deficiency (OTCD) 3 cases, hyperornithinemia-hyperammonemia-homocitrullinuria (3H) syndrome 2 cases, argininosuccinic aciduria (ASA) 1 case, and argininemia 1 case.
Caroli disease 2cases, Wilson’s disease 1 case, maple syrup urine disease (MSUD) 1 case, familial hypercholesterolemia 1 case, Alagille syndrome 1 case, congenital hepatic fibrosis 1 case, cryptogenic cirrhosis 1 case, choledochal cyst 1 case, and fulminant hepatic failure 1 case.
CTP – Child-Turcotte-Pugh; MMA – methylmalonic academia; PELD – Pediatric End-stage Liver Disease; PFIC – progressive familial intrahepatic cholestasis; UCD – urea cycle disorder.